Project cooperationUpdated on 16 April 2026
Dual control colonic delivery system
About
The FHNW School of Life Sciences (a member of Biotechnet) is seeking to out-licence or further develop a dual control colonic delivery system. It is a pharmaceutical dosage form for (per)oral administration that allows targeted release of an active pharmaceutical ingredient (API), or a live biotherapeutic agent in the colonaiming at antiinflammation, immunomodulation, immunosuppression, establishing, re-establishing, and/or modifying the balance of the microbiome in the colon or the physiology of the lower gastrointestinal tract.
See patents and publications:
IP rights: WO2020048979A1
Key publications:
https://doi.org/10.1016/j.ijpharm.2022.122499
https://doi.org/10.1016/j.jconrel.2023.04.047
https://doi.org/10.1016/j.xphs.2024.05.020
Topic
- Biotech, Pharma and Cosmetics
Type
- Research
- Other
Organisation
Similar opportunities
Expertise
- Healthcare
- Biotech, Pharma and Cosmetics
- Food, Beverages and Agriculture
Sonia Thomson
Communication specialist at Biotechnet Switzerland
Muttenz, Switzerland
Partnership
Areas of Interest for international collaboration
Young Ho Kim
Chief Executive Officer at AT-31 BIO Inc.
Daegu, South Korea
Partnership
Areas of Interest for international collaboration
Young Ho Kim
Chief Executive Officer at AT-31 BIO Inc.
Daegu, South Korea